Login to Your Account



Other news to note


Wednesday, April 9, 2014

Daewoong Pharmaceutical Co. Ltd., of Seoul, South Korea, and Bioalliance Pharma SA, of Paris, inked a supply and license deal for Sitavig (acyclovir Lauriad) for commercialization rights in South Korea. Daewoong also will take over registering the drug, for use in recurrent labial herpes, in that region. Bioalliance is eligible for up-front and milestone payments, and the deal also includes a double-digit royalty rate. Specific financial terms were not disclosed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription